Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
Mendizabal M, Haddad L, Gallardo PE, Ferrada A, Soza AA, Adrover R, Aravena E, Roblero JP, Prieto J, Vujacich C, Romero G, Muñoz A, Anders M, Hernández N, Coccozella D, Gruz F, Reggiardo MV, Ruf AE, Varón A, Cartier M, Pérez Ravier R, Ridruejo E, Peralta M, Poncino D, Vorobioff J, Aballay Soteras G, Silva MO. Mendizabal M, et al. Among authors: soza aa. J Med Virol. 2017 Sep;89(9):1590-1596. doi: 10.1002/jmv.24816. Epub 2017 Jun 6. J Med Virol. 2017. PMID: 28370222
Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C.
Méndez-Sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-Ferraz ML, Soza A, Mendes-Correa MC, Chávez-Tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-Avila JF, Contreras F, Moraes-Coelho HS, Parise ER, Bessone F, Uribe M; Latin American Association for the Study of the Liver. Méndez-Sánchez N, et al. Ann Hepatol. 2014 Aug;13 Suppl 2:s4-66. Ann Hepatol. 2014. PMID: 25185535 Free article. Review. No abstract available.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Campbell A, Podsadecki T. Dore GJ, et al. J Hepatol. 2016 Jan;64(1):19-28. doi: 10.1016/j.jhep.2015.08.015. Epub 2015 Aug 29. J Hepatol. 2016. PMID: 26321288 Free article. Clinical Trial.
Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.
Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Piñero F, et al. Liver Int. 2016 Nov;36(11):1657-1667. doi: 10.1111/liv.13159. Epub 2016 Jun 15. Liver Int. 2016. PMID: 27169841
Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study.
Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Piñero F, et al. Ann Hepatol. 2018 Mar 1;17(2):256-267. doi: 10.5604/01.3001.0010.8648. Ann Hepatol. 2018. PMID: 29469048 Free article.
A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America.
Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, McCormack L, Gadano A, Boin ISFF, García P, Silva M; Latin American Liver Research, Education, Awareness Network (LALREAN). Piñero F, et al. Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):443-452. doi: 10.1016/j.clinre.2018.03.014. Clin Res Hepatol Gastroenterol. 2018. PMID: 29773419
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M; LALREAN. Piñero F, et al. Liver Int. 2019 Jun;39(6):1033-1043. doi: 10.1111/liv.14041. Epub 2019 Feb 4. Liver Int. 2019. PMID: 30636361
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M; Latin American Liver Research; Educational and Awareness Network (LALREAN). Mendizabal M, et al. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2554-2563.e3. doi: 10.1016/j.cgh.2020.02.044. Epub 2020 Feb 28. Clin Gastroenterol Hepatol. 2020. PMID: 32113892
76 results